BioTuesdays

Tag - ADMP

Adamis Pharma
Developments

Adamis Pharma gets second CRL for ZIMHI

Adamis Pharmaceuticals (NASDAQ:ADMP) received a second complete response letter (CRL) from the FDA regarding its ZIMHI high dose naloxone injection product for the treatment of opioid overdose. The FDA issued its first...

November 16, 2020
Adamis Pharma
Markets

Dawson James cuts Adamis Pharma PT to $1 from $4

Dawson James reduced its price target for Adamis Pharmaceuticals (NASDAQ:ADMP) to $1 from $4 on the heels of an FDA complete response letter (CRL) for the company’s high-dose naloxone injection product for the treatment...

November 26, 2019
Adamis Pharma
Markets

Maxim cuts Adamis Pharma to hold; withdraws PT

Maxim Group downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “hold” from “buy” and withdrew its previous $3 price target after the company received a complete response letter (CRL) from the FDA regarding the NDA for...

November 25, 2019